NRX Pharmaceuticals Appoints New CMO, Elects Directors
Ticker: NRXPW · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-of-directors, employment-agreement
TL;DR
NRX Pharma shakes up leadership: new CMO, two directors join, and exec gets new contract.
AI Summary
NRX Pharmaceuticals, Inc. announced on January 7, 2025, a significant change in its board of directors and executive compensation. The company appointed Dr. Jonathan Roth as Chief Medical Officer and elected two new directors, Dr. Jonathan Roth and Mr. Jonathan Roth, to its board. Additionally, the company entered into a new employment agreement with Dr. Jonathan Roth.
Why It Matters
These executive and board changes could signal a strategic shift or new direction for NRX Pharmaceuticals, potentially impacting its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership and executive compensation can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan Roth (person) — Appointed Chief Medical Officer and elected as Director
- Mr. Jonathan Roth (person) — Elected as Director
- January 7, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan Roth has been appointed as the new Chief Medical Officer.
How many new directors were elected to the board?
Two new directors, Dr. Jonathan Roth and Mr. Jonathan Roth, were elected to the board.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 7, 2025.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What was the former company name before the name change on October 12, 2017?
The former company name was Big Rock Partners Acquisition Corp.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-14 16:12:17
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 pershare NRXP The Nasdaq Stock Mark
Filing Documents
- nrxp20250114_8k.htm (8-K) — 26KB
- 0001437749-25-001113.txt ( ) — 174KB
- nrxp-20250107.xsd (EX-101.SCH) — 4KB
- nrxp-20250107_def.xml (EX-101.DEF) — 14KB
- nrxp-20250107_lab.xml (EX-101.LAB) — 18KB
- nrxp-20250107_pre.xml (EX-101.PRE) — 14KB
- nrxp20250114_8k_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 7, 2025, Janet Rehnquist resigned as a member of the Board of Directors (" Board ") of NRx Pharmaceuticals, Inc. (the " Company "), effective immediately. Ms. Rehnquist's resignation is not the result of any disagreement with the Company related to the Company's operations, policies, or practices. In connection with the execution of the term sheet with JGS Holdings LLC, controlled by Dallas Sauer & Anita Nunes (" Sauer Nunes "), approved by Ms. Rehnquist, Sauer Nunes is entitled to a designate a member of the Board of Directors of the Company. Management is currently considering nominees designated by Sauer Nunes to be appointed to the Board.
01
Item 8.01 Other Events See Item 5.02 above.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: January 14, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer